From VAD to VRD: Is Transplant Still Needed in the Upfront Setting of Myeloma?

Harsh Parmar; David H Vesole; Noa Biran

doi:10.1097/PPO.0000000000000522

From VAD to VRD: Is Transplant Still Needed in the Upfront Setting of Myeloma?

Cancer J. 2021 May-Jun;27(3):190-195. doi: 10.1097/PPO.0000000000000522.

Authors

Harsh Parmar¹, David H Vesole, Noa Biran

Affiliation

¹ From the Division of Multiple Myeloma, John Theurer Cancer Center at Hackensack Meridian School of Medicine, Hackensack, NJ.

PMID: 34549906
DOI: 10.1097/PPO.0000000000000522

Abstract

High-dose therapy followed by autologous stem cell transplantation (ASCT) is considered the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (MM). With new treatment combinations offering the advantage of improved clinical outcomes of MM patients, the utilization of ASCT is again being addressed in the evolving treatment landscape. In this article, we review the role of frontline ASCT in the management of patients with MM.

Trial registration: ClinicalTrials.gov NCT01208662 NCT04196491.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Hematopoietic Stem Cell Transplantation*
Humans
Multiple Myeloma* / drug therapy
Transplantation, Autologous

Associated data

ClinicalTrials.gov/NCT01208662
ClinicalTrials.gov/NCT04196491